Related references
Note: Only part of the references are listed.Characterization of Severe Asthma Worldwide Data From the International Severe Asthma Registry
Eileen Wang et al.
CHEST (2020)
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc'h et al.
ALLERGY (2020)
International Severe Asthma Registry Mission Statement
G. Walter Canonica et al.
CHEST (2020)
An expert consensus framework for asthma remission as a treatment goal
Andrew Menzies-Gow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis
Richard P. Ramonell et al.
LUNG (2020)
Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma
Wendy C. Moore et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)
Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date
Jean Kim et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab
Georgios Hillas et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Clinical use of biologics for asthma treatment by allergy specialists A questionnaire survey
Merin Kuruvilla et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)
International severe asthma registry (ISAR): protocol for a global registry
J. Mark FitzGerald et al.
BMC MEDICAL RESEARCH METHODOLOGY (2020)
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma
Francesco Menzella et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results
Christopher S. Ambrose et al.
PRAGMATIC AND OBSERVATIONAL RESEARCH (2020)
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study
Lakmini Bulathsinhala et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Role of Biologics in Asthma
Mary Clare McGregor et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
Jean-Pierre Llanos et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
Frank C. Albers et al.
JOURNAL OF ASTHMA (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
J. Mark FitzGerald et al.
LANCET RESPIRATORY MEDICINE (2018)
Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature
Timm Volmer et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Share Paper
